Konishi T, Teruya M, Kawahara M, Itoh A, Asakura R, Araki S, Hojo K, Nouchi T, Takeda Y
Department of Surgery, Showa General Hospital, Tokyo, Japan.
Gan To Kagaku Ryoho. 1998 Mar;25(4):504-15.
At present curative resection is the only radical treatment for gastric cancer, although recently developed combination chemotherapy shows increased activity in treating locally advanced and metastatic disease. Among several combination regimens, those based on biochemical modulation, such as sequential methotrexate/5-fluorouracil or low-dose CDDP/5-fluorouracil, are thought to provide increased efficacy with decreasing adverse reactions in unresectable gastric cancer. Therefore, a prospective randomized clinical trial comparing the prognosis of patients receiving adjuvant multi-agent chemotherapy with those treated only surgically should be pursued for estimation of the clinical benefit of these agents.
目前，根治性切除是胃癌唯一的根治性治疗方法，尽管最近开发的联合化疗在治疗局部晚期和转移性疾病方面显示出更高的活性。在几种联合治疗方案中，那些基于生化调节的方案，如序贯甲氨蝶呤/5-氟尿嘧啶或低剂量顺铂/5-氟尿嘧啶，被认为在不可切除的胃癌中能提高疗效并减少不良反应。因此，应该进行一项前瞻性随机临床试验，比较接受辅助多药化疗的患者与仅接受手术治疗的患者的预后，以评估这些药物的临床益处。
